data13F

DNTH – Dianthus Therapeutics Inc

Held by 2 of 60 tracked investors in their latest 13F filing · 1 counted on Most owned (narrow-view filings excluded)

Investors holding2
Combined shares118,280
Combined reported value$10.4M

DNTH chart by TradingView. Live prices are TradingView's; all other numbers on this page are from 13F filings.

Ownership

Investor% of their portfolioChangeSharesReported valuePeriod
Paul Tudor Jones narrow view 0.04 Added 150.2%93,353$8.2MQ3 2026
Polen Capital 0.02 Added 167.1%24,927$2.2MQ3 2026

Activity: last 4 quarters

PeriodInvestorChangeShares afterEffect on their portfolio (pts)
Q3 2026Paul Tudor Jones narrow view Added 150.2%93,3530.02
Q3 2026Polen Capital Added 167.1%24,9270.01
Q2 2026Paul Tudor Jones narrow view New37,3080.02
Q2 2026Polen Capital Added 126.6%9,3330.00
Q1 2026Polen Capital New4,1190.00

Added: opened or increased

PeriodInvestorChangeShares afterEffect on their portfolio (pts)
Q3 2026Paul Tudor Jones narrow view Added 150.2%93,3530.02
Q3 2026Polen Capital Added 167.1%24,9270.01
Q2 2026Paul Tudor Jones narrow view New37,3080.02
Q2 2026Polen Capital Added 126.6%9,3330.00
Q1 2026Polen Capital New4,1190.00

Reduced: reduced or closed

No tracked investor reduced or closed this position in the last 4 quarters.

History

2 peakQ3 2026: 2 tracked investors
Q1 2026: 1 tracked investorsQ2 2026: 2 tracked investorsQ3 2026: 2 tracked investors
20262026
Tracked investors reporting this stock, by quarter

Shares held, last 8 quarters

InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Paul Tudor Jones93.4K37.3K––––––
Polen Capital24.9K9.3K4.1K–––––

– = not held that quarter. n/a = no holdings report for that quarter (not filed yet, or reported under another manager).